All News

Article

Obinutuzumab drives histologic remission in lupus nephritis

Mrinalini Dey, MBBChir, MA(Hons) Cantab., MRCP, FHEA Jun 06, 2026

At EULAR 2026, investigators are presenting perhaps the most biologically compelling data yet from the REGENCY trial, with evidence that obinutuzumab induces deep intrarenal B-cell depletion alongside markedly higher rates of histological remission.

#EULAR2026 Please find my video on deep tissue depletion and associated histological remission following treatment with Obinutuzumab in #lupus nephritis @RheumNow https://t.co/V9CNdPsLcV https://t.co/WLVFyaSSUE

This study evaluated the risk of flares after sustained drug-free rem in SLE. % of pts w/ reported flares w/n yrs in rem: 48.6% at 2yrs 42.3% at 3yrs 35.2% at 5 yrs Mucocut, msk, renal & immuno - ⬆️affected domain Reassess pts regularly. POS1354 @RheumNow #EULAR2026 https://t.co/DG0yNOW1nh

https://x.com/RHEUMarampa/status/2063348875839103235/photo/1

@RheumNow article further exploring the roe of lung ultrasound for RA-ILD screening as shown through 3 #EULAR2026 abstracts https://t.co/smN8hg51nj

RA-ILD in the Age of Treat-to-Target: Put the Probe on the Chest | RheumNow

What’s new with the 2026 update of reco for vax in AIIRD? Vaccinate as soon as possible Non-live vaccines are safe Hold MTX for upto 2wks to inc vax yield Strong reco for RZV Catch-up vax for HPV in SLE Rotavirus vax for newborns exposed in utero to TNFi @RheumNow #EULAR2026 https://t.co/RZbyvAcYRI

Good performance of #definite #antisynthetase #syndrome ✅+antibody mandatory Possible also does ok @RheumNow #EULAR2026 June 6 #antisynthetase #classifiaction #criteria https://t.co/5sxogTX9YT

Dr. Cavagna presents the 2025 EULAR/ACR Classification Criteria for Anti-Synthetase Syndrome He emphasizes the inportance of ruling out anti-MDA5 Ab & anti-PM/Scl Ab DM since these conditions share overlapping features w/ ASyS. @RheumNow #EULAR2026 https://t.co/AtGRlp5qyW

Do u screen your SLE pts for OP? In this real-world multicenter study, SLE pts who were likely to be tested for BMD were older, had MSK s/sxs, sSJg & longer GC exposure. RFs for OP: LN, higher dse. activity, longer GC use, high cumulative GC dose POS1372 @RheumNow #EULAR2026 https://t.co/pAxhOPGGYs

https://x.com/RHEUMarampa/status/2063309057927024864/photo/1

#EULAR2026 POS1139 Pay attention in #SLE with anti-Sm+ RNP+. Data from 3 RCTs & a cohort: -enriched in Black patients -poor response to B-cell depletion inc. Obi -non-response is assoc. with BAFF-dependent B-cell repopulation. So, use Belimumab -High ferritin = flare @RheumNow https://t.co/3uDMigY8i2

https://x.com/Yuz6Yusof/status/2063280229594890649/photo/1

Abstr LB0003 Off-the-shelf allogeneic NK cell therapy + rituximab in refractory RA, Sjögren disease, and systemic sclerosis. 31 patients. Outpatient administered. RA at 6 months: 71% ACR50, mean CDAI change −36.8. SSc: 100% rCRISS25 response. SjD: 86% ClinESSDAI responders. https://t.co/60046jgYia

https://x.com/synovialjoints/status/2063222707315974230/photo/1

Interesting data on the effect of AB-101 + RTX on refractory RA, SSc and SjD. Curious about long term results and potential position in tx strategies LB0006 @RheumNow #EULAR2026 https://t.co/opbh8yGmwO

#SLE Rx options Determining #MOA #TYK2 #sig w #deucravacitinib #IFN sig in active #SLE ⬇️ in #anifrolumab #upa #deucra #repeat renal #bx in #obinutuzimab ➡️ Clears B cells #Dapriluzimab & other MOAs ⬇️AntiDNA ⬆️complements #EULARbest @RheumNow #EULAR2026 #POS1364, OP0160,336

#EULAR2026 LB0003 CAR-T is not scalable. In a Phase 2a of off-the-shelf AB-101 allogenic NK + low dose conditioning (Cyclo & Flud) + Rituximab: preliminary efficacy & safety profile in severe-refractory RA (N=15), SjD (11), SSc (5). Longer FU & Comparator is needed @RheumNow https://t.co/gQniufREQC

#EULAR2026 LB0004 First BiTE, now TriTE! Tri-specific CC312 CD19/CD3/CD28 (i.e. CD28 co-stimulates Tcell activation) showed deep Bcell depletion, early efficacy & safety in 10 #SLE patients up to 52WKs. Promising but longer FU needed to see if repeat dosing needed @RheumNow https://t.co/6Lbm9LYJrY

JASMINE-SLE: Proof of concept study on Nipocalimab for SLE SRI-4 met at wk 24 for the 15 mg/kg q2w dose va. PBO Improvement of SRI-4 composite & LLDAS at wk 52 LB0007 @RheumNow #EULAR2026 https://t.co/0wzHyid3dy

#EULAR2026 LB0006 Beyond conventional immunosuppressant, a multicentre RCT (N=145) in China showed mTOR-i Sirolimus + SOC met primary endpoint (SRI-4) vs PBO + SOC in #SLE. Favourable safety. Frequent AE: high cholesterol & low WCC. Unclear position in treatment pathway @RheumNow https://t.co/OiFp06467v

https://x.com/Yuz6Yusof/status/2063245455014633559/photo/1

5 top abstracts in #Myositis @eular_org 1 #Nailfold #capillaries as an early marker of #IIM Rx 2 #brepocitinib +RCT #DM 3 & rapid skin improvement #CLASI 4 #Ab may help #IBM but neg primary endpoint 5 #criteria for #antisynthetase #EULAR2026 @RheumNow OP0168, 0166, 0164 POS264

Top 5 abst in #SjD #anifrolumab +RCT #ianalumab LTE Rx sustained #telitatacept +LTE #iana improves u/s parotids #TYK2 sig in#SjD OP0002, 0126, 127, 160 POS0284 #EULARbest #EULAR2026 @RheumNow @eular_org

#EULAR2026 LB0007 Phase 2 RCT of Nipocalimab, an FcRn-i in moderate-to-severe #SLE, with mandatory GC taper =<7.5mg/d by WK16: met primary endpoint at WK24 (SRI-4) vs PBO. Effect size better in Ab+, Ab-High & IFN-High. 23% had IgG<3 at WK58 but SIE. Phase 3 is underway @RheumNow https://t.co/EpgNOHcEqC

Do you target #DORIS / remission in #SLE pts #EULAR2026 @RheumNow @eular_org

Topics

All News

Obinutuzumab drives histologic remission in lupus nephritis

Do you get our email newsletter?